UPClytics
View all cases

UPC CFI 1511/2025

Nov 10, 2025·EP2590626 · LIPOSOMES WITH LIPIDS HAVING AN ADVANTAGEOUS PKA-VALUE FOR RNA DELIVERY

Case details
Status
Oral Phase
Action
Counterclaim for revocation
Category
Counterclaim for revocation
Parties
Claimants
Representatives
Respondents
Representatives
Division
The Hague LD
Technology
  • Chemistry
    Biotechnology · Pharmaceuticals
Language
English
First decided
Feb 25, 2026
EPO Opposition
  • Dennemeyer & Associates S.A.Withdrawn2016-07-28
How this compares
The court's record for this kind of case, counted in first-instance rulings. A figure in brackets is the number of rulings a rate rests on.
Patent revokedMedian days to first decision
All UPC37% (34/91)124
The Hague LDLockedLocked
Judge Edger BrinkmanLockedLocked
Judge Margot KokkeLockedLocked
Judge Stefan SchillingLockedLocked
Judge Martin SchmidtLockedLocked

At the UPC: Pfizer Group (31 cases)·GlaxoSmithKline Biologicals SA (20 cases)

This dispute contains 2 other proceedings

UPC CFI 1509/2025·UPC CFI 620/2025

2 other defendants litigating the same or a related patent

UPC CFI 1439/2025·UPC CFI 616/2025

Start a free trial to see how each one ended.

More cases: The Hague LD·2025

Decisions
  • 2026-02-25
    Infringement ActionPublic

    Summary: The Hague Local Division issued a procedural order under Rule 9 RoP in GSK's infringement action against Pfizer/BioNTech entities concerning vaccine-related patents, addressing admissibility of submissions in GSK's Reply.

    Show the legal issues (3)
    • Late-filed submissions Rule 9 RoP
    • Cryo-TEM images admissibility
    • Expert opinion admissibility
Document titleDatePublic
Oral procedure opened2026-09-03Not public
Interim procedure closed2026-09-03Not public
Receipt2026-08-06Not public
Cover sheet2026-08-06Not public
Document2026-08-06Not public
Receipt2026-07-15Not public
Cover sheet2026-07-15Not public
Document2026-07-15Not public
Receipt2026-07-08Not public
Cover sheet2026-07-08Not public